{"disease":{"id":"breast-tumors","name":"breast tumors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07524114","title":"Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT06805812","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT02568267","title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":534,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT02225470","title":"Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":530,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT07030569","title":"RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT04482309","title":"A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":477,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01174121","title":"Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":332,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02404441","title":"Phase I/II Study of PDR001 in Patients With Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":319,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03412877","title":"Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":285,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06726148","title":"Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":280,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04925284","title":"Study of XB002 in Subjects With Solid Tumors (JEWEL-101)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":269,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT03568656","title":"Study to Evaluate CCS1477 in Advanced Tumours","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"CellCentric Ltd.","has_results":false},{"nct_id":"NCT06577987","title":"Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Circle Pharma","has_results":false},{"nct_id":"NCT07570966","title":"Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":217,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07288359","title":"Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":205,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07029399","title":"A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":205,"lead_sponsor_name":"NiKang Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06239467","title":"First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"OnKure, Inc.","has_results":false},{"nct_id":"NCT03752398","title":"A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":198,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT05262400","title":"A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":192,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04132960","title":"Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":186,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT00620594","title":"A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":183,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02187991","title":"Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":169,"lead_sponsor_name":"US Oncology Research","has_results":true},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT02646748","title":"Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":159,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT00626106","title":"QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"NantCell, Inc.","has_results":true},{"nct_id":"NCT03517488","title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT05584644","title":"A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07218003","title":"A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4","phase":"PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":149,"lead_sponsor_name":"Rondo Therapeutics","has_results":false},{"nct_id":"NCT07038369","title":"A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":134,"lead_sponsor_name":"Atavistik Bio, Inc","has_results":false},{"nct_id":"NCT03329950","title":"A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":132,"lead_sponsor_name":"Celldex Therapeutics","has_results":false},{"nct_id":"NCT05868226","title":"PRE-I-SPY Phase I/Ib Oncology Platform Program","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":124,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false},{"nct_id":"NCT06614751","title":"A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":112,"lead_sponsor_name":"Danatlas Pharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT07156253","title":"Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd","has_results":false},{"nct_id":"NCT03255070","title":"A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":106,"lead_sponsor_name":"Ambrx, Inc.","has_results":false},{"nct_id":"NCT06970561","title":"Analysis of Recurrence of Intraductal Papilloma Treated With Vacuum-assisted Rotary Excision","phase":"","overall_status":"COMPLETED","enrollment_count":106,"lead_sponsor_name":"Wuhan Children's Hospital","has_results":false},{"nct_id":"NCT03514121","title":"FPA150 in Patients With Advanced Solid Tumors","phase":"EARLY_PHASE1","overall_status":"TERMINATED","enrollment_count":95,"lead_sponsor_name":"Five Prime Therapeutics, Inc.","has_results":true},{"nct_id":"NCT06857669","title":"Clinical Explorative Optical Breast Investigations","phase":"NA","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Region Skane","has_results":false},{"nct_id":"NCT03849469","title":"A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT06910657","title":"IDOV-Immune for Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"ViroMissile, Inc.","has_results":false},{"nct_id":"NCT07064018","title":"Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":67,"lead_sponsor_name":"University of California, Irvine","has_results":false},{"nct_id":"NCT00807859","title":"Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT07209020","title":"HealiAid Collagen Wound Dressing in Patients Undergoing Breast Tumor Surgery","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Maxigen Biotech Inc.","has_results":false},{"nct_id":"NCT01291420","title":"Dendritic Cell Vaccination for Patients with Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"University Hospital, Antwerp","has_results":false},{"nct_id":"NCT04660929","title":"CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Carisma Therapeutics Inc","has_results":false},{"nct_id":"NCT07260058","title":"Immune Cell Therapy for Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.","has_results":false},{"nct_id":"NCT02719691","title":"Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"University of Colorado, Denver","has_results":true},{"nct_id":"NCT05877599","title":"A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06472700","title":"Endoscopic Extirpation of Benign Breast Tumors Using a Lateral Chest Wall Incision","phase":"","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT02891681","title":"Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment","phase":"NA","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT02834247","title":"A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":41,"lead_sponsor_name":"Calithera Biosciences, Inc","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}